Press releases
GeNeuro: financial information and business update for the second quarter 2020
Geneva, Switzerland, July 23, 2020, 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today reported on its 2020 second quarter cash position and issued a business update.
https://geneuro.ch/data/news/2020.07.23-GeNeuro-PR-Q2-2020-EN-Final.pdf
GeNeuro announces the publication in Science Advances of data establishing clear link between human endogenous retroviral proteins and psychotic disorders
Geneva, Switzerland, 21 July 2020 – 08:00am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis, today announced data showing the etiological interplay between human endogenous retroviral (HERV) proteins and the emergence of psychotic phenomena in mice.
https://geneuro.ch/data/news/2020.07.21-GeNeuro-PR-Fondamental-EN-final.pdf
GeNeuro enrolls first patient in temelimab Phase 2 multiple sclerosis trial in collaboration with the Karolinska Institutet’s Academic Specialist Center (ASC)
Geneva, Switzerland, June 25, 2020 – 7:30 am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS), today announces the inclusion of the first patient in its Phase 2 trial of temelimab in MS at the Karolinska Institutet’s Academic Specialist Center (ASC), in Stockholm, Sweden.
https://geneuro.ch/data/news/2020.06.25-GeNeuro-MSResumption-EN-VF.pdf
GeNeuro Announces the Approval of all Resolutions proposed at the AGM
Geneva, Switzerland, May 28, 2020 – 6:30pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis, today announced the approval by shareholders of all resolutions proposed at its Annual General Meeting (AGM) of May 27, 2020.
https://geneuro.ch/data/news/2020.05.28-GeNeuro-AGM-28052020-ENG.pdf
GeNeuro: financial information and business update for the first quarter 2020
Geneva, Switzerland, April 27, 2020 – 7.30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), today reported on its 2020 first quarter cash position and issued a business update.
GeNeuro appoints MS clinical development expert Dr. David Leppert as Chief Medical Officer
Geneva, Switzerland, April 21, 2020 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on understanding and stopping the causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis , today announces the appointment of the experienced medical and industry professional Prof. David Leppert, MD and Professor of Neurology, as Chief Medical Officer.
https://geneuro.ch/data/news/GeNeuro-PR-CMO-appointment-EN.pdf